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A B S T R A C T
An 80-year-old male underwent a transcatheter aortic valve implantation (TAVI) for severe senile aortic
stenosis. Six weeks after the surgery, he was readmitted to our institution because of a high-grade fever.
Transesophageal echocardiography revealed thickening of all three leaﬂets of the aortic prosthesis and
mobile mass on the leaﬂet, and Streptococcus sanguis was identiﬁed from his blood culture. Therefore, he
was diagnosed with prosthetic valve endocarditis (PVE) and received intensive intravenous antibiotic
therapy. Because he did not respond to the pharmacological therapy, surgical aortic valve replacement
(AVR) was indicated although it was considered a relatively high-risk procedure. Herein, we report on
the successful surgical AVR in this patient using a pericardial valve after removal of the infected
prosthetic valve, and discuss some issues related to this rare complication after TAVI.
<Learning objective: Transcatheter aortic valve implantation (TAVI) is a highly effective procedure for
patients with symptomatic severe aortic stenosis who are at high risk or deemed inoperable. Because it
only requires limited surgical invasiveness, the risk of prosthetic valve endocarditis (PVE) after TAVI is
thought to be low. However, PVE can occur even early after TAVI. We present our recent such case and
discuss some issues related to this rare complication.>
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Recently in Japan, transcatheter aortic valve implantation
(TAVI) has become available for patients with severe aortic
stenosis who are deemed inoperable or who have too high risk for
conventional surgical aortic valve replacement (AVR). TAVI is a
minimally invasive procedure in which surgical incisions are limited
and cardiopulmonary bypass is usually unnecessary. Furthermore,
because it can be performed quickly, the patients have less chance of
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is rare. We experienced a case of TAVI complicated with early post-
procedural PVE, which subsequently required surgical AVR.
Case report
An 80-year-old male presented for elective TAVI for symptom-
atic severe aortic stenosis. Preoperative transthoracic echocardi-
ography (TTE) demonstrated severe, tricuspid, and calciﬁed aortic
stenosis with a peak transvalvular pressure gradient of 108 mmHg
(mean 64 mmHg) and a calculated aortic valve area of
0.86 cm2. In addition, he had multiple co-morbidities including
chronic kidney disease (estimated glomerular ﬁltration ratio:
33.9 mL/min/1.73 m2), and a remote history of cerebral infarction,
bronchial asthma, hypertension, and prostatic cancer. Since
preoperative coronary angiography showed severe stenosis ofs reserved.
Fig. 1. Transthoracic echocardiography long-axis view. Masses were identiﬁed attached to the prosthetic valve leaﬂets.
Fig. 2.
Infected prosthesis explanted during the operation. A large-sized mass
was seen attached to the aortic surface on one of the leaﬂets.
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intervention to the proximal left anterior descending artery was
performed [1]. Although the predicted operative mortality was
2.98% according to the Society of Thoracic Surgeon’s risk score, he
was deemed at high risk for surgical AVR because of the
aforementioned multiple co-morbidities in addition to his severe
dementia. However, he was considered to be a relatively good
candidate for TAVI by our heart team.
Thus, we performed a TAVI with a transfemoral approach using
a 26 mm Edwards Sapien XT valve (Edwards Lifesciences, Irvine,
CA, USA). His postoperative course was uneventful except for the
fact that he required permanent pacemaker implantation on
the 11th postoperative day because he had persistent complete
atrio-ventricular block. Post-TAVI echocardiography demonstrat-
ed only trivial paravalvular aortic regurgitation with excellent
prosthetic valve function. Thereafter, he was discharged.
Two weeks after discharge, the patient presented at a local
clinic with a high-grade fever and loss of appetite. He was initially
diagnosed with a urinary tract infection, and given oral antibiotics
for two weeks. In spite of this medication, he continued to have
fever and was readmitted to our hospital. Laboratory results
showed a slightly elevated white blood cell count (10,580/mL) and
elevated C-reactive protein (CRP) of 9.1 mg/dL. Transesophageal
echocardiography (TEE) demonstrated thickening of all three
leaﬂets of the aortic prosthesis and medium-sized mobile mass on
the aortic side of two of the three leaﬂets (6–9 mm; Fig. 1). The
degree of paravalvular leakage remained the same, deﬁned as only
trivial. There were no ﬁndings of aortic root abscess. A diagnosis of
early PVE was made, and treatment with empirical antibacterial
therapy (vancomycin 1 g every 24 h and ampicillin 1 g every 12 h,
intravenously) was initiated. After Streptococcus sanguis was
identiﬁed from his blood culture, his antibiotics regimen was
changed to continuous infusion of penicillin G (15 million units/24 h,
intravenous continuously) and gentamycin (60 mg every 12 h,
intravenously). This regimen was switched to ceftriaxone (1 g every
12 h) because the patient developed kidney dysfunction (serum
creatinine of 3.0 mg/mL). His serum creatinine gradually improveddown to 1.3 mg/mL thereafter. Subsequently, oral screening
revealed six dental caries, and all the affected teeth were extracted.
In addition, brain magnetic resonance imaging demonstrated
new acute cerebral infarction in the bilateral frontal lobes and
lateral lobes, although the patient was totally neurologically
intact. Furthermore, repeated TTE detected a large-sized mass on
a native mitral valve leaﬂet in addition to those on the aortic
prosthetic valve.
After 4 weeks of the intensive antibiotic therapy, we decided to
perform surgical AVR for refractory PVE. Under standard cardio-
pulmonary bypass with ascending aortic and bicaval cannulations,
we removed the previous prosthesis (Fig. 2) and the retracted
native calciﬁed aortic cusps, and performed AVR with a bovine
pericardial tissue valve (Carpentier Edwards Perimount bioprosth-
esis 21 mm). We also performed a vegetectomy of the mitral
leaﬂet. Total cardiopulmonary bypass and aortic cross clamp times
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antibiotic therapy of ceftriaxone (1 g every 12 h) for another
4 weeks. His postoperative course was uneventful and he was
discharged free of antibiotics.
Discussion
Since TAVI was ﬁrst successfully performed by Cribier in 2002
[2], the number of patients with severe aortic stenosis treated with
TAVI continues to increase. PVE after TAVI is relatively rare because
TAVI usually does not require cardiopulmonary bypass, requires
minimal skin incision, and can be done quickly. However, a few
such cases have been reported because of the sheer number of
TAVIs being performed worldwide [3–7]. The incidence of PVE
after TAVI ranges from 0% to 2.3% in previous reports [4]. Loverix
et al. reported a pooled analysis in patients with PVE after TAVI
(n = 29), where blood culture was negative in 12 out of 29 cases
(41.4%) and Enterococcus faecalis was the most common microor-
ganism (27.6%) [3]. The causes of PVE included other infections,
previous endoscopic procedures, prosthesis misplacement in the
outﬂow tract of the left ventricle, and dental procedures without
antibiotic prophylaxis. Eight patients underwent surgical AVR and
the remaining patients were treated conservatively with anti-
biotics. The overall 30-day mortality was 22.3%. PVE is a rare but
serious complication after TAVI, and it entails high morbidity and
mortality. In general, it is difﬁcult to treat PVE pharmacologically
and it usually requires surgical intervention as the deﬁnitive
treatment. Given the fact that many patients undergo TAVI because
they are at too high risk to undergo conventional AVR, the risk
posed by AVR for patients in this subgroup who suffer from PVE is
even greater. In addition, AVR may not be indicated in some
patients with PVE who are deemed inoperable. Therefore, the
prevention of PVE is an extremely pressing issue. In the current
case, the PVE was presumably caused by untreated dental caries
without appropriate antibiotic therapy. It should be noted that
preoperative dental screening is important for patients undergoing
not only AVR but even TAVI. Needless to say, it is also crucial to
maintain strict sterile conditions during the TAVI procedure and an
appropriate antibiotic prophylaxis is essential postoperatively
[8]. According to the PARTNER trial [9], although paravalvular
leakage was much more common after TAVI than AVR, there were
no differences in the incidence of PVE between TAVI and AVR at
2-year follow-up. However, the patients, especially who developed
signiﬁcant paravalvular leakage after TAVI, should be closely
monitored because it is well known that paravalvular leakage is
one of the most important risk factors for PVE.In conclusion, PVE early after TAVI is rare. However, when it
does occur, it usually requires the surgical removal of the infected
prosthesis and AVR. Although the causes of PVE vary, our case
suggests the importance of preoperative dental screening and care
in patients undergoing TAVI.
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